Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The status of targeted genes and the association between targeted genes and clinicopathological features in Chinese lung cancer patients remains to be elucidated.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The status of 10 targeted genes was evaluated by next‐generation sequencing (NGS) in 884 non‐small cell lung cancer (NSCLC) patients. The relationship between gene alterations and clinicopathological characters was analyzed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Overall, 684 (77.4%) patients harbored gene alterations, and <i>EGFR </i> (510, 57.7%) was found to be the most common type of mutation followed by <i>KRAS </i> (91, 10.3%), <i>HER2 </i> (38, 4.3%), <i>PIK3CA </i> (32, 3.6%), <i>ALK </i> (21, 2.4%), <i>BRAF </i> (10, 1.1%), <i>ROS1 </i> (5, 0.6%), <i>RET </i> (5, 0.6%), <i>MET </i> (4, 0.5%) and <i>NRAS </i> (1, 0.1%) Gene alterations were more frequent in females, non‐smokers and adenocarcinoma (<i>P </i> < 0.001). <i>EGFR </i> mutations were associated with women, non‐smokers, normal level of serum tumor markers, and adenocarcinoma <i>(P </i> < 0.001). Patients without lymph node metastasis (<i>P </i> = 0.012), or early stage disease (<i>P </i> < 0.001) exhibited a higher <i>EGFR </i> mutation rate. <i>KRAS </i> mutations tended to arise in men (<i>P </i> < 0.001), smokers (<i>P </i> < 0.001) and patients with higher levels of serum tumor markers (<i>P </i> = 0.048). A mucus‐producing component was associated with <i>KRAS </i> (<i>P </i> < 0.001), <i>ROS1 </i> (<i>P </i> = 0.033) and <i>ALK </i> (<i>P </i> < 0.001) alterations. <i>ALK </i> and <i>ROS1 </i> rearrangements were more frequent in micropapillary structures (<i>P </i> = 0.004, <i>P </i> = 0.012). <i>BRAF </i> mutation was associated with advanced disease patients and micropapillary structure (<i>P </i> < 0.001). <i>PIK3CA </i> mutation was more likely to be found in elderly patients (<i>P </i> = 0.014). Some patients had synchronous gene alterations, including <i>EGFR/PIK3CA </i>, <i>EGFR/HER2 </i>, <i>HER2/KRAS </i>, <i>EGFR/KRAS </i>, <i>EGFR/ROS1 </i>, <i>EGFR/NRAS </i>, <i>KRAS/PIK3CA </i>, <i>KRAS/PIK3CA/HER2. </i></p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Most patients had at least one genetic alteration, and individual patients harbored synchronous mutation. Each gene alteration had unique clinicopathological characteristics.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significant findings of the study</h3><p>This study revealed the frequency and distribution of 10 targeted gene abnormalities and their association with clinicopathological parameters of Chinese non‐small cell lung cancer (NSCLC) patients in eastern China.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> What this study adds</h3><p>Some rare synchronous mutations were detected in our study by next‐generation sequencing (NGS).</p></section>

RNF213 gene mutation in circulating tumor DNA detected by targeted next‐generation sequencing in the assisted discrimination of early‐stage lung cancer from pulmonary nodules

RNF213 gene mutation of circulating tumor DNA in early diagnosis of NSCLC using targeted next-generation sequencing

Clinical significance of multi-sample next-generation sequencing for detection of gene mutations in non-small cell lung cancer

A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules

Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Detection of EGFR Gene Mutation Status from Pleural Effusions and Other Body Fluid Specimens in Patients with Lung Adenocarcinoma

Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non‐small cell lung cancer

Accurate diagnosis of pulmonary nodules using a non-invasive DNA methylation test

Abstract 5394: Detecting pulmonary malignancy against benign nodules using non-invasive cfDNA fragmentomics assay

[Value of peripheral blood rare cell EGFR gene amplification detection in the evaluation of benign and malignant pulmonary nodules]

Detecting pulmonary malignancy against benign nodules using noninvasive cell-free DNA fragmentomics assay

Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer

Accurate Diagnosis of Pulmonary Nodules Using a Noninvasive DNA Methylation Test.

Noninvasive diagnosis of pulmonary nodules using a circulating tsRNA‐based nomogram

A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA

Cell-free DNA assay for malignancy classification of high-risk lung nodules.

Validating a Targeted Next-Generation Sequencing Assay and Profiling Somatic Variants in Chinese Non-Small Cell Lung Cancer Patients

Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution

A Cost-Effective and Non-Invasive pfeRNA-Based Test Differentiates Benign and Suspicious Pulmonary Nodules from Malignant Ones

MA17.03 Identifying Genomic Alteration and Inter-Tumor Heterogeneity of Multiple Primary Lung Cancers by Targeted NGS of Tumor Tissue and Ctdna